RxDoctor Payments DataLook up a doctor →

Adelaide Hebert, MD

Pediatric Dermatology · Bellaire, TXNPI 1427005453

Payments from drug & device makers

$3,649,392in general payments, 2019–2025

Across 2,365 payments — averaging $1543.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.1M
  • Dermavant Sciences, Inc.$477K
  • Arcutis Biotherapeutics, Inc.$372K
  • Incyte Corporation$322K
  • Takeda Pharmaceuticals U.S.A., Inc.$300K
  • Amgen$181K
  • plus $927K from 45 others
$53,605in research payments, 2019–2025

Across 34 payments — averaging $1576.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$29K
  • Regeneron$14K
  • Novartis$9K
  • Bausch Health US, LLC$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer486$1,070,761
Dermavant Sciences, Inc.730$476,853
Arcutis Biotherapeutics, Inc.169$372,274
Incyte Corporation210$321,896
Takeda Pharmaceuticals U.S.A., Inc.64$299,559
Amgen18$181,197
Janssen Research & Development, LLC16$125,572
Sun Pharmaceutical Industries Inc.88$124,925
AbbVie46$93,557
E.r. Squibb & Sons, L.L.C.11$91,807
Eli Lilly50$70,294
Galderma Laboratories, L.p.65$58,763
Organon55$52,728
Ortho Dermatologics, A Division Of Bausch Health US, LLC39$41,581
Sanofi US Services Inc.14$37,547
Verrica Pharmaceuticals Inc.17$32,746
Almirall LLC25$31,066
Dermira, Inc.17$27,301
Boehringer Ingelheim20$27,170
LNHC, Inc25$26,060
LEO Pharma Inc.38$23,406
Novartis59$15,494
VYNE Pharmaceuticals Inc.9$9,327
Janssen Global Services, LLC4$5,511
Boehringer Ingelheim International GmbH2$4,671
Kowa Pharmaceuticals America, Inc.3$4,241
LEO Pharma AS1$4,230
Pierre Fabre Pharmaceuticals, Inc.7$3,995
Lilly USA, LLC5$3,530
Amryt Pharma Holdings Ltd1$2,600
Janssen Scientific Affairs, LLC3$2,079
UCB SA1$1,750
Botanix SB Inc3$1,148
Regeneron Healthcare Solutions, Inc.16$1,117
Sanofi17$800
Biogen5$346
UCB, Inc.7$319
Biofrontera Inc.2$271
Krystal Biotech Inc2$238
Journey Medical Corporation3$133
Sanofi-aventis U.S. LLC1$100
Mayne Pharma Commercial LLC2$85
Biohaven Pharmaceuticals, Inc.1$84
Johnson & Johnson1$70
Hill Dermaceuticals, Inc.1$48
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$36
Genentech USA, Inc.1$27
Shire North American Group Inc1$26
EPI Health, LLC1$23
Bristol Myers Squibb1$17
Medline Industries LP1$13

How this compares

Too few pediatric dermatology providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,977
Medicare patients
119
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric dermatology in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →